$16.10
-0.68-4.05%
Last update: Oct 30, 6:49 PM
Ultragenyx Pharmaceutical Inc (RARE) Stock Price, Quote, News & History
RARENASDAQ
FDA approves Ultragenyx's Fayuvi for Sanfilippo syndrome Type A. Review commercial plans, $3.95 million pricing.
You can purchase shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) through any online brokerage.
Other companies in Ultragenyx Pharmaceutical’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Ultragenyx Pharmaceutical has a consensus price target of $46.81.
The stock price for Ultragenyx Pharmaceutical (NASDAQ: RARE) is $16.1 last updated October 30, 2026 at 6:49 PM EDT.
There are no upcoming dividends for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical does not have any upcoming earnings scheduled.
There is no upcoming split for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic...
